P-2258. Characterizing real world infection risk in multiple myeloma patients receiving teclistamab

There was a nonsignificant trend toward increased immune effector cell-associated neurotoxicity syndrome (ICANS) and increased use of steroids in the infected group. 10 patients in the infected group discontinued teclistamab (p=0.013) and 3 died (p=0.108, Table 2).

also in 5,406 other papers